Financings

Abpro Corp. has filed to raise $69 million from an IPO.

Cellectis SA closed an underwritten offering for net proceeds of approximately $163.7 million.

Codexis Inc. said it priced an underwritten public offering with net proceeds expected to be approximately $32.3 million.

Constellation Pharmaceuticals Inc. disclosed a $100 million financing.

Enterprise Therapeutics Ltd. raised £29 million (US$41 million) in a series B round.

Intec Pharma Ltd. said it priced an underwritten public offering for estimated gross proceeds of $35.4 million.

Magenta Therapeutics Inc. has closed a $52 million series C financing.

Mereo Biopharma Group plc sets terms for a $70 million IPO by offering 4 million American depositary shares priced at $17.62 each.

Morphosys AG set terms for its U.S. IPO, planning to raise $200 million from the sale of 8.3 million American depositary shares at $24.12 each.

Novavax Inc. priced an underwritten public offering for gross proceeds of $50 million.

Polarityte Inc. priced an underwritten public offering for expected proceeds of approximately $32.5 million.

Surface Oncology Inc. has established the terms for an IPO and plans to raise up to $84 million by offering 6 million shares priced between $13 and $15.

Synlogic Inc. is selling 3.28 million shares at $9.15 each to a mutual fund investor in a registered direct offering. The company anticipates gross proceeds of approximately $30 million.

Tessa Therapeutics raised an additional $50 million, to bring the total generated from its funding round to $130 million.

Tracon Pharmaceuticals Inc. completed its private placement for gross proceeds of about $38.7 million.

Unity Biotechnology Inc. filed an S-1 with the SEC seeking to raise up to $85 million, including overallotments, in an IPO.

Deals

Alexion Pharmaceuticals Inc. is offering SEK7.1 billion (US$855 million) to shareholders of Sweden's Wilson Therapeutics AB in a bid to acquire its phase III therapy for Wilson's disease, a rare copper-excess condition.

Bristol-Myers Squibb Co. is collaborating with the Harvard Fibrosis Network of the Harvard Stem Cell Institute to develop new therapies for fibrotic diseases, including fibrosis of the liver and heart.

Epidestiny Inc. granted Novo Nordisk AS an exclusive global license to its sickle cell disease program, EPI-01.

Immunoprecise Antibodies Ltd. acquired Modiquest Research BV for €7 million (US$8.6 million).

Glaxosmithkline plc is divesting Strimvelis, the only approved gene therapy in Europe – along with the rest of its rare disease gene therapy portfolio – to Orchard Therapeutics Ltd., in return for a 19.9 percent stake in the company.

Loxo Oncology Inc. and Illumina Inc. are partnering to develop and commercially launch a multigene panel companion diagnostic for broad tumor profiling.

Novartis AG is offering $8.7 billion offer to buy Avexis Inc., a company developing a gene therapy for spinal muscular atrophy.

Tesaro Inc. licensed the rights to its PARP inhibitor, Zejula (niraparib), in Israel to Medison Pharma Ltd. for all indications excluding prostate cancer.

Tyme Technologies Inc. is collaborating with The Joseph Ahmed Foundation to test SM-88 in bone or soft tissue sarcomas, with an initial focus on Ewing's sarcoma.

Veracyte Inc. is collaborating with Loxo Oncology Inc. and will provide it, through its Afirma Xpression Atlas platform, information regarding thyroid cancers with TRK fusions and RET alterations to be used in the development of its targeted therapies.

Wave Life Sciences Ltd. and Deep Genomics Inc. are collaborating to develop oligonucleotide drugs for the treatment of genetic neuromuscular disorders.

Zealand Pharma A/S is collaborating with Roche Diabetes Care, a unit of Basel, Switzerland-based Roche Holding AG, on the phase III program for dasiglucagon as a treatment of congenital hyperinsulinism.

. . . And More

Another Alzheimer's disease potential therapy came up short as azeliragon (formerly TTP-488), the orally active small-molecule antagonist of receptor for advanced glycation end products, or RAGE, from Vtv Therapeutics Inc., failed in part A of the phase III STEADFAST study.

Pfizer Inc. joined the Trinetx global health research network, a consortium of health care organizations, biopharmaceutical companies and contract research organizations collaborating to enhance clinical trial design and accelerate patient recruitment

Sanofi SA plans to invest €350 million (US$431 million) in a new vaccine manufacturing facility in Toronto.

The pivotal phase III ECHO-301/KEYNOTE-252 study evaluating Incyte Corp.'s epacadostat in combination with Merck & Co. Inc.'s Keytruda (pembrolizumab) in individuals with unresectable or metastatic melanoma failed a review by the external data monitoring committee.